Press Releases

PARIS & CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 11, 2022-- Regulatory News : NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the " Company "), a clinical-stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that

PARIS & CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 4, 2022-- Regulatory News : NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘ Company ’’) , a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced

PARIS & CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 2, 2022-- Regulatory News : NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the “ Company ”), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced the

Data presented at the 2022 Annual Meeting of the American Association of Cancer Research New data from an open-label preclinical study in mice evaluating the changes in immune-related genes induced by multiple combinations of NBTXR3, anti-PD-1, anti-LAG-3, and anti-TIGIT showed that groups that

PARIS & CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 8, 2022-- Regulatory News : NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘ Company ’’) , a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major

New data from Expansion Study 102 in high-risk, LA-HNSCC patients highlights potential clinical benefit of NBTXR3 showing a median Overall Survival reaching 23 months in evaluable patients; Data with minimum follow-up of one year for full study population anticipated in mid-2023 Pivotal Phase III

Conference Call and Webcast to be Held at 8:00 A.M. EDT /2:00 P.M CET on March 31, 2022 PARIS & CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 16, 2022-- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘ Company ’’)  (Paris:NANO) (NASDAQ:NBTX) , a late-stage clinical biotechnology company pioneering

Data published in Clinical and Translational Radiation Oncology Peer-reviewed clinical case study reported preliminary data on the first-in-human administration of NBTXR3 for the treatment of pancreatic cancer not eligible for surgery, demonstrating feasibility with no treatment-related toxicity

Data published in the International Journal of Nanobiotechnology Peer-reviewed preclinical data in an anti-PD-1 resistant lung cancer model show that adding NBTXR3 to a combination of radiotherapy, anti-PD-1, and anti-CTLA-4 produced significant antitumor effects against both primary and secondary

Evaluation of NBTXR3 for global registration in priority head and neck cancer pathway proceeds with the first European patient randomized in global phase III NANORAY-312 study; US and Asia site activation expected in 2022 Priority NBTXR3 plus anti-PD-1 combination program poised to advance as the